Small cap News

Barclays warned that disruptions in Hormuz could remove 13-14 million bpd, with Brent possibly rising toward $110 if the disruptions persist.

Sentiment was also lifted by expectations tied to the Golden Dome missile-defense initiative, which could boost demand for satellite and space infrastructure.

Merck’s acquisition of Terns underscores strong big-pharma demand for blood-cancer assets, as Pfizer also expands its oncology pipeline.

Among Thursday’s catalysts are initial jobless claims data and remarks from several Federal Reserve officials.

The firm registered two new trials combining Anktiva with off-the-shelf iNKT cell therapy in adults with pneumonia, including those with sepsis or ARDS.

The company said it has developed a new liquid biopsy method, and in a blinded validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Analysts said the war risk premium is still ebbing and flowing, with some expecting stabilization if escalation risks ease.

Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

The FDA warning letter cited television advertising and podcast remarks suggesting broader cancer uses beyond Anktiva’s approved indication.

The company's comprehensive loss per share of C$0.33 during the quarter missed analysts' estimate of a loss of C$0.18 per share.

Energy remained the key driver, with Brent crude rising 4.6% to $104 and WTI gaining 4.8% to $92.

Ocugen said 12-month Phase 2 trial data showed its drug OCU410 significantly reduced lesion growth at the dose planned for Phase 3.

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

The company said it expects first production of gold in late 2028 at its Bilboes gold project in Zimbabwe.

Small-cap explorers, including TPET, EONR, BATL and INDO outperformed large-cap energy names amid geopolitical supply concerns.

The comments come amid the firm’s strategy to position Anktiva as a platform immunotherapy that works along with vaccines, checkpoint inhibitors and chemotherapy.

AMC said improving box office trends support expectations that 2026 could become the biggest year for theatrical attendance since 2019, helped by a stronger upcoming film slate.

LUNR is drawing retail optimism as investors bet on a NASA contract for a lunar terrain vehicle.

Traders flagged unusual futures activity ahead of Trump’s announcement, including $1.5 billion in S&P futures and $580 million in oil contracts.

Betaville’s “uncooked” alert from last week flagged potential interest in BioCryst from a U.S.-based biopharma with a market cap above $15 billion.

YZi Labs alleged “catastrophic” control failures at CEA Industries, insider payments, and a deal that may restrict shareholder transparency.

Anavex presented new data from its Phase IIb and Phase III blarcamesine programs, showing that preservation of brain volume is associated with improved patient outcomes.

Brent crude topped $113 as Trump issued a 48-hour ultimatum to Iran over the Strait of Hormuz.

Investors will monitor U.S. construction spending data for January on Monday.

If ORBS’ share price remains below the $1 threshold for more than 30 days, the company risks receiving a deficiency notice from Nasdaq.

Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.

Gemini Space Station’s earnings came after the shareholders filed a class-action lawsuit against the company over its “abrupt corporate pivot” to prediction markets, changes in leadership, and sudden layoffs.

Early trial data showed immune activation in initial patients, with Anktiva boosting lymphocyte levels.

Oil stocks declined in premarket trading as crude prices pulled back on easing Middle East tensions and prospects of additional supply.

AMC is restructuring its business through theater closures and debt refinancing, after losing nearly all its value from its 2021 meme-stock peak.

Wall Street closed lower but off lows, while geopolitical uncertainty, oil supply risks, and Fed policy outlook kept markets on edge.

The company’s cash stood at $71.8 million at the end of the year, marking the company’s strongest balance sheet so far.

The company announced a 1-for-100 reverse stock split of its outstanding common stock and publicly traded warrants.

Financial results also showed that Strive Asset Management added another 317 Bitcoin to its balance sheet over the past week.

The company stated that the early-stage program positions it in a segment set for continued investment and innovation.

The rally was driven by escalating attacks on energy facilities across the Gulf, including damage in Qatar, Iran and Abu Dhabi.

U.S. stock futures edged lower late Wednesday following a sharp sell-off as inflation concerns, rising oil prices and geopolitical tensions weighed on sentiment.

Swarmer priced its IPO at $5 per share to raise $15 million, but the parabolic rise since its debut has seen its market capitalization rise to nearly $680 million.

The firm said it was revising its outlook across multiple crypto-linked equities after slashing its 12-month price targets on Bitcoin and Ethereum.

Artelo Biosciences secured a fully-funded study to evaluate the effects of its peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.

The company said that the Air-Launched Rapid Response Missile is expected to deliver nearly hypersonic speed and long range at a fraction of the cost of other hypersonic weapons.

Rising fuel costs, with U.S. diesel above $5 per gallon, are adding to inflation concerns ahead of the Federal Reserve’s policy meeting on Wednesday.

Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival events recorded.

Market sentiment remains cautious, with bearish retail positioning amid warnings that oil shocks historically triggered sharp S&P 500 drawdowns.

Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

USO bucked the trend with gains in premarket trading even as most oil stocks slipped despite oil climbing above $100.

Intelligent driving usage surged over 80% month-on-month, with engagement crossing 200 million km for the first time.

Analysts turned bullish, citing strong data and the drug's potential to expand into earlier treatment settings.